Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Summary

This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.

Timeline

Start

2022-01-01

Primary completion

2024-04-01

Completion

2024-04-01

Outcome

Met primary endpoint

paper Metformin and empagliflozin halted the decline in eGFR at study end with adjusted mean difference ± SE: 8.91 ± 1.92 (p˂0.001) PMID 41373013 ↗

paper and 5.1 ± 1.89 (p = 0.03), respectively, compared to control group. PMID 41373013 ↗

Publications

• Mahboub BM, Refaie AF, El-Haggar SM, Hafez YM, Mostafa TM. Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial. Diabetol Metab Syndr. 2025 Dec 10;18(1):17. doi: 10.1186/s13098-025-02040-9.
• El-Damanawi R, Stanley IK, Staatz C, Pascoe EM, Craig JC, Johnson DW, Mallett AJ, Hawley CM, Milanzi E, Hiemstra TF, Viecelli AK. Metformin for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013414. doi: 10.1002/14651858.CD013414.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	10 mg	Oral
Subject	Metformin	Small molecule	1000 mg	Oral

Indications